Sugi Predict

Sugi Predict / Targets / FAH

FAH

Fumarylacetoacetase · P16930 · FAH on Sugi Atlas →

0 patent compounds predicted against FAH, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to FAH by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Alirocumab and Plaque Burden In Familial Hypercholesterolaemia PHASE4COMPLETED
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia PHASE3COMPLETED
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk PHASE3COMPLETED
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) PHASE3COMPLETED
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE) PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Rosuvastatin to Decrease Residual Immune Activation in HIV Infection PHASE2UNKNOWN
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) PHASE2RECRUITING
A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders PHASE1COMPLETED
8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia PHASE1COMPLETED
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis EARLY_PHASE1COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin) nanWITHDRAWN
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Familial Hypocalciuric Hypercalcemia: Clinical Aspects and Evolution nanCOMPLETED
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia nanRECRUITING
Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography ) nanUNKNOWN
Systemic Biomarkers of Brain Injury From Hyperammonemia nanRECRUITING
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) nanUNKNOWN
The Effect of Nursing Empowerment Program nanCOMPLETED
Study of Protein Translocation in Patients With Beta-Oxidation Disorders nanCOMPLETED
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 nanUNKNOWN
MyRareDiet A Novel Diet Tracking Tool nanNOT_YET_RECRUITING
Genetic and Metabolic Disease in Children nanRECRUITING
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS nanRECRUITING
Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway nanCOMPLETED
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis nanRECRUITING
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada nanRECRUITING
Aortic Stenosis in Subjects With Heterozygous Familial Hypercholesterolemia on Prolonged Treatment With Statins nanUNKNOWN
Lysosomal Acid Lipase Deficiency in Risk Groups nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a FAH binder may also engage these)

ProteinNameSimilarity
P25093 — 1.000 P25093 →
A5PKH3 — 1.000 A5PKH3 →
Q94272 — 1.000 Q94272 →
P35505 — 0.997 P35505 →
Q4WHT8 — 0.997 Q4WHT8 →
Q00770 — 0.996 Q00770 →
Q6H7M1 — 0.987 Q6H7M1 →
Q1ZXQ1 — 0.984 Q1ZXQ1 →
P16638 — 0.970 P16638 →
A0A4P8DJE6 — 0.970 A0A4P8DJE6 →
O93918 — 0.970 O93918 →
Q4X1D4 — 0.970 Q4X1D4 →
H1AE13 — 0.969 H1AE13 →
Q99KI0 — 0.969 Q99KI0 →
A7KAL8 — 0.969 A7KAL8 →
Q09WE7 — 0.969 Q09WE7 →
Q8X1T3 — 0.969 Q8X1T3 →
Q9UUE1 — 0.968 Q9UUE1 →
P11832 — 0.968 P11832 →
Q99798 — 0.968 Q99798 →
L7HUY5 — 0.968 L7HUY5 →
Q2UD95 — 0.968 Q2UD95 →
Q8JH71 — 0.968 Q8JH71 →
Q4WPE6 — 0.968 Q4WPE6 →
Q7ZXP9 — 0.968 Q7ZXP9 →
A6ZQ59 — 0.968 A6ZQ59 →
Q6FUD0 — 0.968 Q6FUD0 →
O88428 — 0.968 O88428 →
A1DA84 — 0.968 A1DA84 →
A0A0U3AL34 — 0.968 A0A0U3AL34 →